Edward W. Cowen, MD, MHSc, senior clinician and acting branch chief, Dermatology Branch, National Institutes of Health, speaks on cytokines involved in the pathophysiology in pustular psoriasis and off-label therapy use.
There are several important cytokines involved in the pathophysiology of pustular psoriasis, with current treatment relying on a trial and error approach for the off-label use of psoriasis therapies, said Edward W. Cowen, MD, MHSc, senior clinician and acting branch chief, Dermatology Branch, National Institutes of Health.
Transcript
Can you describe the pathophysiology of pustular psoriasis and how it compares with psoriasis?
So, targeting specific cytokines, including TNF [tumor necrosis factor], IL [interleukin]-12, IL-23, and IL-17, this has risen as a very effective way to manage classic plaque psoriasis. Pustular psoriasis may share overlapping pathways of inflammation, but we've also learned over the past several years that IL-36 is a particularly important cytokine in patients who have an inherited form of pustular psoriasis.
How has off-label use of approved psoriasis therapies fared in addressing treatment needs for those with pustular psoriasis?
Most of the data for use of the newer targeted therapies for pustular psoriasis is really based on anecdotal reports or small open-label trials. So, in part this is due to the relative rarity of the pustular forms of psoriasis, but this has also resulted in a bit of a trial-and-error approach to see which treatment might work best for a given patient with either localized or generalized disease.
Patients With Advanced, Recurrent Melanoma May Experience Lasting AEs From ICM Therapy
May 9th 2024A cross-sectional, mixed-methods study found that adverse effects (AEs) can occur even after 1 year of treatment with immune checkpoint modulator (ICM) therapy in patients with melanoma.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Goal Achievement in T1D Management Boosts Self-Efficacy, Self-Care Among Emerging Adults
May 9th 2024Findings from the FAMS-T1D study demonstrate that structured goal-setting and achievement significantly enhance self-efficacy and self-care in emerging adults who have type 1 diabetes (T1D).
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Integrating RECIST and Clinician Approaches Boosts NSCLC Research
May 8th 2024Outcomes among patients with stage IV non–small cell lung cancer as evaluated within clinical trials via Response Evaluation Criteria in Solid Tumors (RECIST) and clinician response criteria in observational studies were compared for their concordance and reliability.
Read More